Statistics

Total Visits

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens99

Select a period of time:

Number of views in the range

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens52

Views

Views
December 20251
January 20261
February 20260
March 202612
April 20261
May 202612
June 202625
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States27
Netherlands6
France6
United Kingdom2
Italy2
Colombia2
Argentina1
Côte d'Ivoire1
Dominican Republic1
Ecuador1
 

Top cities views

Views
San Jose10
Groningen6
Columbus4
Aubervilliers3
Tower Hamlets2
Abidjan1
Ciudad Guayana1
Lisbon1
Monterrey1
Pasto1